MTB 9655
Alternative Names: MTB-9655Latest Information Update: 18 Jan 2024
At a glance
- Originator Metabomed
- Class Antineoplastics; Small molecules
- Mechanism of Action ACSS2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Jan 2024 EpiVario acquires acetyl co-A synthetase-2 inhibitor ("ACSS2i") portfolio including MTB 9655 from Metabomed
- 03 Jun 2022 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumous presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR - 2022)